Non-viral Gene Delivery Technologies Market Size, Share & Trends | Forecast Report [2030]

Non-viral Gene Delivery Technologies Market Size, Share & Trends | Forecast Report [2030]

Market Size & Trends (2025 Outlook)

The global non-viral gene delivery technologies market was valued at USD 3.70 billion in 2024 and is projected to reach USD 7.11 billion by 2030, growing at a CAGR of 12.29%. This growth is largely fueled by advancements in genome editing (e.g., CRISPR/Cas9) and the increasing focus on personalized medicine.

Key Drivers of Growth

• Adoption of LNPs and polymers for safer, scalable alternatives to viral vectors.

• Demand for treatments for rare genetic diseases and chronic illnesses.

• Post-COVID-19 momentum from mRNA vaccines (Moderna, Pfizer) that validated non-viral systems.

• Increasing global investment in nanomedicine, particularly gold nanoparticles, carbon nanotubes, and RNA-based delivery platforms.

Get a Free Sample Report PDF: https://www.theresearchinsights.com/reports/non-viral-gene-delivery-technologies-market-1048/request-sample

Industry Shifts & Innovations

• Intellia Therapeutics, Editas Medicine, Arcturus Therapeutics, and Cellectis are developing in vivo non-viral delivery platforms for gene editing.

• New regulatory frameworks from FDA and EMA are making it easier — though still rigorous — to bring non-viral therapies to market.

• Approvals like Inclisiran (Leqvio) for hypercholesterolemia have demonstrated real-world success of siRNA-based, non-viral therapies.

COVID-19 Impact

• Accelerated the adoption of LNPs and nucleic acid-based delivery systems.

• Showcased the scalability and efficacy of non-viral platforms for vaccine and therapeutic applications.

Market Characteristics & Concentration

• Rapid tech evolution in LNPs, CRISPR delivery, and polymeric vectors is reshaping the landscape.

• Regulatory bodies are adapting, but safety/efficacy data remain key for approvals.

• Companies are expanding portfolios with RNA nanoparticles, electroporation, and self-assembling systems.

• North America and Europe are leaders, while Asia-Pacific (China, India) is rising fast with increasing R&D investments and supportive policy environments.

Segment Insights

Mode

• Chemical delivery methods (e.g., LNPs, polymers, lipoplexes) are leading in 2024 due to:

  • Low immunogenicity

  • High payload capacity

  • Scalability and cost efficiency

Applications

• Research dominates due to demand for gene function and regulation tools.

• Therapeutics is the fastest-growing segment, especially for:

  • Chronic diseases

  • Oncology

  • Rare genetic disorders

End Use

• Research & Academic Institutes hold the largest share (48.11% in 2024), expected to grow fastest as non-viral methods become mainstream in labs.

• Biopharma companies are expanding therapeutic pipelines using scalable non-viral systems.

Regional Trends

North America (41% market share)

• Dominated by the U.S. with robust biotech, funding, and FDA support.

• mRNA vaccine success has paved the way for clinical application of non-viral methods.

Europe

• Major players: UK, Germany, France

• Key trends: Personalized medicine, national genomic research investments, supportive EMA frameworks.

  • UK: Strong CRISPR research and clinical trial activity.

  • Germany: Advanced manufacturing and biotech.

  • France: Focus on cancer, rare disease, and neurological disorders.

Asia-Pacific

• China: CRISPR leadership, strong government backing.

• Japan: High R&D intensity, precision medicine focus.

• India: Cost-effective healthcare solutions, growing clinical trial infrastructure.

Middle East & Africa

• UAE, Qatar, Saudi Arabia: Investing in biotech diversification.

• Emphasis on genomics, cancer therapy, and rare disease solutions via non-viral vectors.

• Collaborations with global biotech firms are increasing.

Key Companies

Leading companies driving innovation and market growth:

• Thermo Fisher Scientific

• GenScript

• Danaher

• Merck KGaA

• Bio-Rad Laboratories

• Altogen Biosystems

• Lonza

• Sonidel

• SIRION BIOTECH

• Innovative Cell Technologies

Notable Developments

• Poseida Therapeutics (Oct 2024): Non-viral editing for hereditary angioedema.

• Moderna x Generation Bio (Mar 2023): Strategic partnership for non-viral genetic medicines.

• ProBio x UCI Therapeutics (Sep 2024): Joint efforts in NK cell gene delivery using viral and non-viral platforms.

Market Outlook & Forecast